Evidence map›Paper›PMID 34650138›Full record

ArticleScientific reports2021

Results of an early second PCR test performed on SARS-CoV-2 positive patients may support risk assessment for severe COVID-19.

Barak Mizrahi, Maytal Bivas-Benita, Nir Kalkstein, Pinchas Akiva, Chen Yanover, Yoav Yehezkelli, Yoav Kessler, Sharon Hermoni Alon, Eitan Rubin, Gabriel Chodick

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Barak Mizrahi *KI Research Institute, 11 Hazayit st, Kfar Malal, Israel. barak@kinstitute.org.il.
Maytal Bivas-Benita *KI Research Institute, 11 Hazayit st, Kfar Malal, Israel.
Nir KalksteinKI Research Institute, 11 Hazayit st, Kfar Malal, Israel.
Pinchas AkivaKI Research Institute, 11 Hazayit st, Kfar Malal, Israel.
Chen YanoverKI Research Institute, 11 Hazayit st, Kfar Malal, Israel.
Yoav YehezkelliKI Research Institute, 11 Hazayit st, Kfar Malal, Israel.
Yoav KesslerShraga Segal Department of Microbiology and Immunology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Sharon Hermoni AlonMaccabi Healthcare Services, Tel-Aviv, Israel.
Eitan RubinShraga Segal Department of Microbiology and Immunology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Gabriel ChodickMaccabi Institute for Research and Innovation, Tel-Aviv, Israel.
IMI TAMI Institute for Research and Development · ILBen-Gurion University of the Negev · ILMaccabi Institute for Health Services Research · ILTel Aviv University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Identifying patients at increased risk for severe COVID-19 is of high priority during the pandemic as it could affect clinical management and shape public health guidelines. In this study we assessed whether a second PCR test conducted 2-7 days after a SARS-CoV-2 positive test could identify patients at risk for severe illness. Analysis of a nationwide electronic health records data of 1683 SARS-CoV-2 positive individuals indicated that a second negative PCR test result was associated with lower risk for severe illness compared to a positive result. This association was seen across different age groups and clinical settings. More importantly, it was not limited to recovering patients but also observed in patients who still had evidence of COVID-19 as determined by a subsequent positive PCR test. Our study suggests that an early second PCR test may be used as a supportive risk-assessment tool to improve disease management and patient care.

Indexed as

AdolescentAdultAgedAged, 80 and overCOVID-19COVID-19 Nucleic Acid TestingFemaleHumansMaleMiddle AgedPrognosisRisk AssessmentSARS-CoV-2Severity of Illness IndexTime FactorsYoung Adult

Identifiers

PMID34650138
PMCPMC8516879
OpenAlexW3207050361

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.